Antitumor activity of the novel oral highly selective Wee1 inhibitor Debio 0123

Presented at AACR 2019, Atlanta, GA, US

Colin O’Dowd¹, Gerald Gavory¹, Frank Burkamp¹, Adam Treder¹, Caroline Boyd¹, Tim Harrison¹, Frederic Massière², Astrid Glück², Anita Thorimbert², Christophe Chardonnens², Andréa Zaffalon², Stefania Rigotti², Robert Mader², Grégoire Vuagniaux², Anne Vaslin²

1. Almac Discovery, Belfast, UK,
2. Debiopharm International SA, Lausanne, Switzerland